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Abstract In the last few years, the treatment of castration-resistant prostate carci-
noma (CRPC) has changed completely. The approval of docetaxel and sub-
sequent investigation in this field have led to development of new agents that
have demonstrated an improvement in overall survival in the post-docetaxel
setting, such as cabazitaxel and abiraterone. Radium-223 chloride is a radio-
isotope that has recently shown efficacy after docetaxel and in patients unfit
for docetaxel, with improvements in overall survival and the time to the first
skeletal-related event, compared with placebo, without increasing toxicity.
These findings have made this agent a new option for treatment of these
patients in the near future.
1. Introduction
Prostate carcinoma is the most common ma-
lignancy in men in Western countries, accounting
for more than 240 000 cases in the US in 2011.[1]
Although its mortality is relatively low compared
with other malignancies, it is currently the second
leading cause of cancer death in men, with more
than 28 000 deaths in the US in 2011.[1]
Castration-resistant prostate carcinoma (CRPC)
is defined by the following criteria: castrate serum
levels of testosterone (<50ng/mL); three consecutive
rises in the levels of prostate-specific antigen (PSA) 1
week apart, resulting in two 50% increases over the
nadir; antiandrogen withdrawal for at least 4 weeks
for flutamide and for at least 6 weeks for bicaluta-
mide; PSA progression despite consecutive hormo-
nal manipulations; and progression or appearance
of two or more bone lesions in bone scintigraphy,
or in soft tissue, following the Response Evalu-
ation Criteria In Solid Tumors (RECIST) criteria,
or nodes >2 cm in diameter.[2] This progression
occurs despite androgen deprivation therapy, and
in this setting the estimated overall survival (OS)
is about 18 months when docetaxel-based treat-
ment is used.[3]
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Nevertheless, this does not mean the tumor is
fully resistant to subsequent hormonal therapies:
that is why the term ‘hormone-resistant prostate
cancer’ has been replaced by the term ‘castration-
resistant prostate cancer’. Even with castrate le-
vels of testosterone, prostate cancer cells can still
be hormone driven. Several studies have shown
amplification and/or overexpression of androgen
receptor (AR), intratumoral synthesis of an-
drogens acting in a paracrine manner, and epi-
genetic alterations that influence AR activity.[4-6]
Lowering of circulating testosterone levels is initially
effective at blocking tumor growth, but prostate
cancer will progress despite this.[7] In the past few
years, several agents have been approved by regu-
latory agencies in the metastatic CRPC (mCRPC)
setting post-docetaxel, such as abiraterone[8] and
cabazitaxel.[9] Recently, a phase III trial of abirater-
one in patients with mCRPC in the pre-docetaxel
setting has also proven its superiority to placebo-
prednisone.[10]
Because of the high skeletal morbidity of these
patients, research has also focused on delaying or
preventing skeletal-related events (SREs). Bisphos-
phonates, mainly zoledronic acid, have proven
efficacy in this situation.[11] Recently, denosumab,
a monoclonal antibody targeting the receptor ac-
tivator of nuclear factor kB (RANK) ligand, has
proven superior to zoledronic acid in delaying
SREs, and in 2010 it was approved by theUSFood
and Drug Administration (FDA) for prevention
of SREs in patients with bone metastases of solid
tumors.[12] Specifically, denosumab prolonged the
time to a pathologic fracture, spinal cord com-
pression, radiation therapy to bone, and surgery
to bone, as these were the events defined as SREs
and analyzed in the trial.[12] With a different dos-
age and schedule of administration, denosumab
has also been approved by the FDA as a treat-
ment to increase bone mass in men at high risk of
fracture receiving androgen deprivation therapy
for nonmetastatic prostate cancer. Table I sum-
marizes agents that have a proven survival benefit
in mCRPC.
Radium-223 chloride (223-Ra) is an alpha-
emitting radiopharmaceutical that delivers high-
energy irradiation with a short range, and therefore
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beta-emitting radiopharmaceuticals, such as sa-
marium-153 and strontium-89.[13] In this review,
we focus on the trials involving this radiopharma-
ceutical, from the initial phase I trial to the pivotal
phase III trial recently presented at the European
Society of Medical Oncology (ESMO) meeting
in 2011.
2. Phase I Trial
This trial was published in 2005[14] and recruited a
total of 25 patients with bonemetastases frombreast
and prostate cancer (10 females and 15 males).
Each of the patients received a single injection of
223-Ra, as part of a cohort dosage escalation
schedule. Patients were included at each of the
following doses: 46, 93, 163, 213, or 250kBq/kg,
and followed for 8 weeks. There was no dose-
limiting hematotoxicity at any dosage level; revers-
ible myelosupression occurred in some patients,
with nadirs 2–4 weeks after injection and full re-
covery within the 8-week follow-up period. Two
patients experienced grade 3 neutropenia; thrombo-
cytopenia was observed only at level 1, even in the
highest-dose patients. Other common adverse
events (AEs) were transient diarrhea (in 10 of the
25 patients), bone pain, including a ‘flare’ effect
(in 9 patients), nausea (in 5 patients) and vomit-
ing (in 5 patients).
Seven of the 25 patients had a serious AE
(SAE). Five of these were considered to be related
to the extent of the malignant disease. One breast
cancer patient experienced an episode of supra-
ventricular arrhythmia, which was uncertainly
related to the radiopharmaceutical (as the patient
had a previous story of arrhythmia), and another
breast cancer patient suffered from grade 3
vomiting and grade 3 leucopenia after treatment
at the highest dose level, but made a full recovery.
An important finding was that alkaline phos-
phatase (ALP) levels were consistently reduced
after 223-Ra injection, mostly in patients with ele-
vated baseline levels, suggesting antitumoral activity
and a possible prolongation of progression-free
survival (PFS). Preclinical data also suggested anti-
tumoral activity against skeletal metastases, lead-
ing to life extension.[15] Pain score data in this
trial were improved with 223-Ra, with more than
50% of patients reporting benefits in pain control
compared with baseline.
Therefore, 223-Ra was well tolerated at the
studied doses, and data regarding pain control,
little toxicity, and potential antitumoral activity
led to further development of this agent.
3. Phase II Trials
The first phase II trial with 223-Ra, enrolling
only CRPC patients, was published in 2007.[16]
This trial included patients who were due to re-
ceive external-beam radiotherapy to relieve pain
from bone metastases, and they were randomized
to receive either four repeated monthly injections
of 223-Ra, at a dose of 50kBq/kg, or repeated in-
jections of placebo, together with radiation therapy.
The main objectives were a reduction in bone-
specific ALP levels and prolongation of the time
to occurrence of SREs.
Sixty-four patients were recruited between
February 2004 and May 2005; 33 were assigned
to 223-Ra and 31 to placebo. Twenty-eight patients
in the 223-Ra group and 21 in the placebo group
completed all four injections. The reasons for
discontinuation were mainly progressive disease
(in two patients in the 223-Ra group and four in
the placebo group), patient preference (in four
patients in the placebo group), cardiac disease (in
two patients in the 223-Ra group and one in the
placebo group) and confusion (in one patient in
each group).
The median relative change in the bone ALP
level from baseline to 4 weeks after the last study
injection was -65.6% and 9.3% in the 223-Ra and
placebo groups, respectively (p< 0.0001). This trial
also included evaluation of the levels of other serum
tumor markers, such as total ALP, procollagen-I
N-propeptide (PINP), C-terminal crosslinking
telopeptide of type I collagen (CTX-I), and type I
collagen crosslinked C-telopeptide (ICTP), and
they all were significantly reduced in the 223-Ra
group.
The median time to the first SRE was 14 weeks
in the 223-Ra group and 11 weeks in the placebo
group. The hazard ratio for the time to the first
SRE, adjusted for baseline covariates, was 1.75
(p = 0.065). The median relative change in the
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PSA level from baseline to 4 weeks after the last
study injection was -23.8% in the 223-Ra group
and 44.9% in the placebo group (p = 0.003). The
median time to PSA progression was 26 weeks
for 223-Ra compared with 8 weeks for placebo
(p = 0.048). The median OS was 65.3 weeks for
223-Ra and 46.4 weeks for placebo (p = 0.066),
with an adjusted hazard ratio of 2.12 (p = 0.02).
Myelotoxicity did not differ significantly between
the two groups, and other side effects, such as
vomiting, diarrhea, fatigue, or myalgia, were also
similar. Only constipation was more frequent in
the 223-Ra group.
The second phase II trial has been published
very recently, in 2012.[17] This randomized, double-
blind, phase II study aimed to investigate the
dose-response relationship and pain-relieving ef-
fect of 223-Ra in CRPC patients with bone meta-
stases. The primary endpoint was the pain index
(according to a visual analog scale [VAS] and
analgesic consumption), which was also used to
classify patients as responders or non-responders.
BetweenMay 2005 andDecember 2007, a total
of 100 patients were randomized to receive dif-
ferent doses of a single injection of 223-Ra (5, 25,
50, or 100 kBq/kg). A statistically significant dose
response occurred at week 2 (p= 0.035). At week 8,
40%, 63%, 56%, and 71% of the above dose groups,
respectively, were pain responders (pain index £4).
Of the responders, 30%, 42%, 44%, and 52% in the
above dose groups, respectively, achieved a com-
plete response (pain index 1) or a marked response
(pain index 2). Up to week 8, fewer patients in the
high-dose groups required increases in analgesia,
compared with the lower-dose groups. Pain res-
ponders in all dose groups showed improvement in
the Brief Pain Inventory (BPI) functional inter-
ference index. On the daily VAS at week 8, pain
decreased by a mean of 30, 31, 27, and 29mm in
responders in the above dose groups, respectively.
About 97% of patients reported at least one
AE. Hematologic events were generally not se-
vere, with slightly greater rates of thrombopenia,
leucopenia, and neutropenia in the two highest-
dose groups. The most frequent hematologic AEs
were anemia (11% of patients) and a hemoglobin
decrease (15%). The most frequent non-hemato-
logic AEs were nausea, vomiting, diarrhea, con-
stipation, peripheral edema, and bone pain, with
no difference across dose groups. Although sur-
vival was not an objective of this trial, the median
OS was 50 weeks, which did not differ between
dose groups.
These two trials suggested efficacy of 223-Ra
in patients with mCRPC, in both symptomatic
improvement and prolongation of survival, and
with a favorable safety profile. These findings led
to development of the placebo-controlled phase
III trial ALSYMPCA (Alpharadin in Sympto-
matic Prostate Cancer).
4. Phase III Trial (the ALSYMPCA Trial)
The results of an interim analysis of the
ALSYMPCA phase III trial were presented at the
ESMO meeting in 2011 and are yet to be pub-
lished.[18] This trial enrolled patients with con-
firmed symptomatic CRPC, with at least two bone
metastases and no known visceral metastases,
who had previously received chemotherapy with
docetaxel or were unfit for docetaxel therapy.
Patients were stratified according to ALP levels,
previous bisphosphonate use, and prior docetaxel
use. The primary endpoint was the OS. Second-
ary endpoints were the time to the first SRE, time
to total ALP progression, total ALP response,
total ALP normalization, time to PSA pro-
gression, safety, and quality of life (QoL).
A total of 921 patients were randomized on a 2 : 1
basis to receive 223-Ra at a dose of 50 kBq/kg,
administered as six injections at 4-week intervals,
or placebo. The interim results were analyzed
after 314 events, and in light of these results the
Independent DataMonitoring Committee (IDMC)
recommended stopping the trial early because there
was evidence of a significant OS benefit favoring
223-Ra.
The median OS was 14 months in the 223-Ra
group versus 11.2 months in the placebo group
(HR 0.695, p= 0.00185). The time to the first SRE
was also longer in the 223-Ra group, 13.6 versus
8.4 months (HR 0.61, p = 0.00046). All of the
other secondary endpoints also favored patients in
the 223-Ra group. According to previous strat-
ification factors, there was benefit across all sub-
groups in the 223-Ra treatment arm.
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Eighty-eight percent of patients in the 223-Ra
group and 94% in the placebo group presented
with some kind of AE. Grade 3 or 4 AEs were
seen in 51% of the 223-Ra group and 59% of the
placebo group. SAEs were seen in 43% of the 223-
Ra group and 55% of the placebo group. No AE
was more frequent in the treatment arm than in
the placebo arm.
Updated results of this trial were presented at
the American Society of Clinical Oncology (AS-
CO) meeting held in Chicago (IL) in June
2012.[19] The OS benefit was consistent with pre-
viously reported data (14.9 vs 11.3 months, HR
0.695, p = 0.00007). Also, the time to the first SRE
was significantly longer in the 223-Ra arm (12.2
vs 6.7 months, HR 0.64, p < 0.0001). No new
safety signals were identified. Data regarding
QoL are still pending.
5. Future Research Directions
The closing of the phase III ALSYMPCA trial
may lead to early approval of 223-Ra by regulatory
agencies in mCRPC patients. Its low toxicity pro-
file and benefit in OS makes it a very attractive
agent to test in tumors with a high occurrence of
bone spreading, such as breast cancer.
In prostate carcinoma, 223-Ra is already being
tested in CRPC patients in combination with
docetaxel chemotherapy in a phase I–IIa trial
(BC1-10 [A Study of Alpharadin With Doce-
taxel in Patients With Bone Metastasis From
Castration-Resistant Prostate Cancer (CRPC)]),[20]
which was initiated in June 2010 and is being
conducted in the US. The objective of this study is
to establish the optimal dose of 223-Ra for this
treatment combination, to confirm the safety of this
strategy, and to explore potential efficacy. Safety
and bone-marker data are expected throughout
2012.
In breast cancer, a phase II trial (BC1-09 [A
Study of Alpharadin in Breast Cancer Patients
With Bone Dominant Disease no Longer Con-
sidered Suitable for Hormone Therapy]) is being
conducted in endocrine-refractory patients with
bone-dominant metastatic disease. This 23-pa-
tient open-label trial aims to elucidate the effect
of 223-Ra in bone markers, and also the safety of
this approach in breast cancer patients. At the
2011 San Antonio Breast Cancer Symposium,
data for tumor makers were presented.[21] Patients
were scheduled to receive four injections of 223-Ra
at a dose of 50kBq/kg every 4 weeks. Treatment
with 223-Ra consistently reduced urine levels of
NTX (N-terminal telopeptide) and bone ALP
levels, and there were no SAEs related to the study
drug. Functional imaging results, additional bone
marker data, and patient-reported outcomes are
being analyzed.
Several agents have been approved in the past
few years or will probably be approved soon
(table I). Cabazitaxel seems to be established as a
chemotherapeutic option after docetaxel, at least
until the results of the phase III trial comparing
cabazitaxel with docetaxel as first-line therapy in
mCRPC are known.[22] Although abiraterone is
approved in the post-docetaxel setting, it will pre-
sumably move to the pre-docetaxel scenario in view
of the results of the COU-AA-302 (Abiraterone
Acetate in Asymptomatic or Mildly Symptomatic
Patients With Metastatic Castration-Resistant
Prostate Cancer) trial.[10] Another new hormo-
nal therapy, MDV3100 (enzalutamide), was also
proven to have OS benefit in mCRPC patients
that have progressed on docetaxel in the phase III
AFFIRM (Safety and Efficacy Study of MDV3100
in Patients With Castration-Resistant Prostate
Cancer Who Have Been Previously Treated With
Docetaxel-based Chemotherapy) trial;[23] there is
also a phase III trial of this drug in the pre-docetaxel
setting (PREVAIL [A Safety and Efficacy Study of
Oral MDV3100 in Chemotherapy-Naive Patients
with Progressive Metastatic Prostate Cancer]),[24]
which is still enrolling patients. Therefore, combi-
nation and sequencing strategies will be critical for
optimal management of these patients.
6. Conclusions
Radiopharmaceuticals in prostate carcinoma
have traditionally been used with mainly a pal-
liative intent, to improve symptomatic control in
patients with bone metastases. These drugs also
have considerable toxicities, mostly hematologic,
that could cause SAEs and also handicap future
therapeutic possibilities.[25,26] None of the pre-
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viously tested agents, such as samarium-153 or
strontium-89, have clearly demonstrated a bene-
fit in OS.
223-Ra, an alpha-emitting agent, has recently
shown a consistent effect on OS in mCRPC pa-
tients after progression on docetaxel, or in patients
unfit for docetaxel therapy, and symptomatic relief
and prolongation of the time to the first SRE were
significantly greater with 223-Ra therapy. There-
fore, it has become a new therapeutic option in this
setting and hopefully will be available within a
short period of time.
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